Invited Review

Female genital schistosomiasis (FGS): from case reports to a call for concerted action against this neglected gynaecological disease

Vanessa Christineta, Janis K. Lazdins-Heldsb, J. Russell Stothardc, Jutta Reinhard-Ruppd,*

a Centre International de Recherches, d’Enseignements et de Soins en Milieu Tropical (Cires), Akonolinga, Cameroon
b Geneva, Switzerland
c Department of Parasitology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
d Merck, Coinsins, Switzerland

ARTICLE INFO

Article history:
Received 30 December 2015
Received in revised form 22 February 2016
Accepted 23 February 2016
Available online 8 April 2016

Keywords:
Urogenital schistosomiasis
Gynaecology
FGS
HIV/AIDS
Praziquantel
Female genital schistosomiasis

ABSTRACT

In recent years, control of neglected tropical diseases has been increasingly gaining momentum and interventions against schistosomiasis are being progressively scaled-up through expansion of donated praziquantel and preventive chemotherapy campaigns. However, the public health importance of female genital schistosomiasis is not fully recognised nor its control is adequately addressed. Taking a clinical and anatomopathological perspective, we evaluated the available literature to highlight the importance of female genital schistosomiasis and its connections with two sexually transmitted infections of global importance, Human Immunodeficiency Virus (HIV) and Human Papilloma Virus. Outside the long list of clinical descriptive reports beginning in 1899, there is presently a shocking gap in epidemiological assessment and a significant underestimation of the burden of FGS remains. The scarcity of integrated approaches to address female genital schistosomiasis calls for more concerted action in its detection, treatment and prevention alongside other concomitant women’s health issues, otherwise female genital schistosomiasis will remain a neglected gynaecological disease.

© 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Schistosomiasis is a water-borne parasitic disease caused by infection with trematode worms of the genus Schistosoma. The disease was originally described in Egypt by Theodor Bilharz in 1851 and today can be found throughout Africa, South America and Asia (Colley et al., 2014). Infection may affect humans of all ages and genders, and globally it has the highest burden of disease among the 17 recognised neglected tropical diseases (World Health Organization (WHO), 2016b). Owing to a variety of factors underlying an individual’s exposure and infection, there can be substantial differences in prevalence and intensity of infection across communities, as well as an associated spectrum in the severity of disease. These manifestations are determined by a number of causal factors such as the species of schistosome, the duration of infection, host-specific factors that influence immunopathological lesions to the worm eggs and access to praziquantel treatment (Hirayama, 2006). Furthermore, as individuals rarely harbour schistosomiasis alone, prior infection with Schistosoma can increase the severity of other bacterial, protozoal or helminth infections acquired later (Abruzzi and Fried, 2011).

Schistosomiasis can be broadly classified as either acute or chronic presentations (Colley et al., 2014). Upon initial percutaneous infection by cercariae, acute symptoms may include dermatitis, then later non-specific symptoms of fever, headache and cough. Acute symptoms normally resolve in a few weeks but in exceptional cases, death by hyper-infection may occur. As adult schistosomes mature within the body and commence egg deposition, chronic manifestations ensue, typically related to immunopathological lesions and the formation of granulomata in various organs around eggs (Colley et al., 2014). The involvement of the intestinal tract with hepato-splenic disease and the urinary tract with its associated organs is well-known (Centers for Disease Control and Prevention (CDC), 2012 http://www.cdc.gov/parasites/schistosomiasis/disease.html; WHO, 2016, http://www.who.int/mediacentre/factsheets/fs115/en/). Since eggs can be found throughout the body in variable amounts, other clinical and pathological diseases can be found in the heart, lungs, brain and spinal cord as well as in the genital organs of both genders (Barsoum et al., 2013).
The pathological alterations due to the presence of schistosome eggs in the genitalia of women have been defined as a particular entity called female genital schistosomiasis (FGS). In 1997, the Gender Task Force of the Tropical Disease Research Programme (TDR) of the WHO included FGS in a list of scientific areas that deserve higher research priority (Poggensee et al., 1999). Since then, however, the extent of morbidity ascribed to FGS, which can be found in both the lower and upper genital tract, has continued to be insufficiently addressed. Moreover, FGS has failed to be reported at national levels which has hampered an international appraisal. As an unfortunate outcome, prevention and control of FGS is largely disconnected from global efforts to improve the reproductive and sexual health of women. To address this, we attempted to draw together the available literature to give a continental perspective and highlight how FGS should be integrated into a broader vision of improving women’s health.

2. Methodology

PubMed was used as the search tool. The key words used to gather information on FGS in general were ‘female’, ‘genital’ and ‘schistosomiasis’. Only publications treating the clinical and anatomo-pathological aspects of FGS were selected and mapped or displayed in the table. Articles published between 1899 and September 2015 were included. Articles in English, French, German and Spanish were considered. Articles in Portuguese, Japanese or Chinese were included only as cited in Table 1 or Fig. 1. A specific review was performed on FGS attributed to Schistosoma haematobium and its association with HIV infection. The following keywords were used: ‘HIV’ OR ‘acquired immunodeficiency syndrome’ AND ‘schistosomiasis’ OR ‘bilharzia’ or ‘haematobium’.

Owing to their wider implications, publications that addressed schistosomiasis during pregnancy and HPV/cervical cancer, when encountered during the initial literature review, were also inspected but the topic was formalised in the initial search algorithm.

3. An overview of the FGS literature

A total of 193 publications featuring reports on the clinical and pathological presentation of FGS were identified while preparing this review. A considerable proportion describe African cases published during the colonial era (Fig. 1). Some 44 publications were from Europe, USA and Oceania, describing FGS in migrants or travellers coming from schistosomiasis-endemic countries (Table 1). The large majority of the reviewed publications were case reports or case series; the oldest published FGS case was reported in the Lancet in 1899 (Madden, 1899). The analysis of case reports and case series shows that every female genital organ (vulva, vagina, uterine cervix, uterine body, Fallopian tubes and ovaries) can be affected by schistosomiasis. We note that uterine body involvement is greatly under-reported in such reports, being clearly revealed upon comparison with findings from post-mortem studies. These latter studies demonstrate that the most frequently affected gynaecological organs are the uterine cervix and the uterine body, followed by the adnexa and the vulvo-vagina (Charlewood et al., 1949; Gelfand and Ross, 1953; Youssef et al., 1970; Gelland et al., 1971; Edington et al., 1975). Of the three schistosomes of most medical significance, the majority of FGS is caused by S. haematobium but in Brazil, for example, FGS has been shown to be caused by Schistosoma mansoni (Chaves and Palitot, 1964; Coelho et al., 1979; Poggensee et al., 2001; Downs et al., 2011; Goncalves Amorim et al., 2014). In Asia, cases of FGS have also been described as resultant from Schistosoma japonicum. Less important schistosome species such as Schistosoma intercalatum have also been shown to cause FGS (Koller, 1975; Berry, 1976; Yang, 1984; Picaud et al., 1990; Qunhua et al., 2000; WHO, 2016, http://www.who.int/schistosomiasis/genital_schistosomiasis/en/).

Most of the FGS cases reported before 1990 probably underrepresented the real burden of FGS for, in our opinion, they were based on reports from African urban centres or in northern countries where more advanced screening tools were available. Several more recent studies attempted to address this systemic bias by

### Table 1

<table>
<thead>
<tr>
<th>Country of diagnosis</th>
<th>Schistosomiasis infestation origin</th>
<th>Age (years)</th>
<th>Schistosomiasis-associated clinical condition</th>
<th>Schistosoma spp.</th>
<th>Publication reference number</th>
</tr>
</thead>
<tbody>
<tr>
<td>UK</td>
<td>Malawi Lake, Zimbabwe (t)</td>
<td>34, 43, 51, 26</td>
<td>Vulvar granuloma (3 cases), adnexal mass, infertility, tubal</td>
<td>S. haematobium</td>
<td>14, 17, 37, 107, 147, 148, 156, 168, 183</td>
</tr>
<tr>
<td></td>
<td>Zambia, Nigeria, Zimbabwe (m)</td>
<td>39, 37, 31</td>
<td>carcinoma, ectopic pregnancy, teratoma, HPV/HIV infection,</td>
<td>S. haematobium, S. mansoni (1 case)</td>
<td>2, 13, 45, 54, 93, 131, 154</td>
</tr>
<tr>
<td>USA</td>
<td>Senegal, East Africa, Liberia, Guinea, South Africa (m)</td>
<td>27, 20, 28, 29, 22, 20, 63, 32, 37</td>
<td>Cervical dysplasia with HPV, cervical dysplasia with HPV/</td>
<td>S. haematobium, S. mansoni</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HIV, sandy patches, ectopic pregnancy, salpingitis, infertility, perianal fistula, cervical cancer without HPV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>DRC (m), Mauritania (m), Senegal (m), Tunisia (m), Mali (m), Mali (t), Senegal (m)</td>
<td>28, 34, 22, 29, 32, 35, 29, 21, 33, 27</td>
<td>Infertility, cervical dysplasia, tubal obstruction, hydrosalpinx,</td>
<td>S. haematobium, S. mansoni (DRC, 1 case from Senegal)</td>
<td>51, 58, 60, 106, 123, 124, 165</td>
</tr>
<tr>
<td>Germany</td>
<td>Angola, Sierra Leone, Togo (m)</td>
<td>24, 30, 21</td>
<td>Ectopic pregnancy, leiomyoma, infertility, adnexal tumour</td>
<td>S. haematobium</td>
<td>86, 118, 161</td>
</tr>
<tr>
<td></td>
<td>Malawi Lake, Mali (t)</td>
<td>37, 33</td>
<td>Leiomyoma, infertility</td>
<td>S. haematobium</td>
<td>29, 79</td>
</tr>
<tr>
<td>Spain</td>
<td>Nigeria (m) Mali (t)</td>
<td>26</td>
<td>Infertility, vulvitis</td>
<td>S. haematobium</td>
<td>15, 50</td>
</tr>
<tr>
<td>Switzerland</td>
<td>Egypt, Malawi Lake (t)</td>
<td>54, 26</td>
<td>Vulvar granuloma, asymptomatic ovarian and tubal</td>
<td>S. haematobium</td>
<td>28, 76, 105</td>
</tr>
<tr>
<td>Portugal</td>
<td></td>
<td></td>
<td>schistosomiasis, vulvar lesion and cervical lesions</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ovarian schistosomiasis, external genital mass</td>
<td></td>
<td>104, 179</td>
</tr>
<tr>
<td>Belgium</td>
<td>Mali, Senegal (t)</td>
<td>20</td>
<td>Vulvar mass</td>
<td>S. haematobium</td>
<td>39</td>
</tr>
<tr>
<td></td>
<td>Brazil</td>
<td></td>
<td>Hydrosalpinx, tubal schistosomiasis</td>
<td>S. mansoni</td>
<td>136</td>
</tr>
<tr>
<td>Israel</td>
<td>Ethiopia (m)</td>
<td>19</td>
<td>Recto-vaginal fistula</td>
<td></td>
<td>102</td>
</tr>
<tr>
<td>Ireland</td>
<td>Nigeria (m)</td>
<td>31</td>
<td>Ectopic pregnancy, tubal schistosomiasis</td>
<td></td>
<td>67</td>
</tr>
<tr>
<td>Italy</td>
<td>South Tunisia (t)</td>
<td>30, 28</td>
<td>Vaginal mass</td>
<td>S. haematobium</td>
<td>23</td>
</tr>
<tr>
<td>New Zealand</td>
<td>Malawi Lake</td>
<td></td>
<td>Adnexal mass, vulvar lesion</td>
<td>S. haematobium</td>
<td>52, 111</td>
</tr>
</tbody>
</table>

m, migrants; t, travellers; HPV, human papilloma virus; HIV, human immunodeficiency virus.
measuring the prevalence of cervical schistosomiasis in several rural communities known to be endemic for schistosomiasis. These studies assessed the cervical form of FGS (diagnosed by biopsy except in the Talaat study (Talaat et al., 2004) in the frame of schistosomiasis screening studies targeting the general population in regions known to be endemic for schistosomiasis in Madagascar, Tanzania, Malawi, Niger and Egypt. In these studies, cervicovaginal schistosomiasis prevalence ranged from 33% (95% confidence interval (CI): 19–51) in Madagascar to 75% (95% CI 65–87) in Niger, with Tanzania and Egypt in between (Renaud et al., 1989; Leutscher et al., 1998; Poggensee et al., 2000; Talaat et al., 2004; Kjetland et al., 2005).

Another systematic bias apparent in the literature is that most FGS cases were reported in women less than 30 years of age, however, this probably reflects the age of the studied population and not the true age distribution of FGS. Symptoms attributable to FGS have been reported in young children (Hegertun et al., 2013) particularly the vulvo-vaginal forms (Berry, 1966; Al-Adnani and Saleh, 1982; Gouzouv et al., 1984), as well as in post-menopausal women (Berry, 1966; McKee et al., 1983; Arora et al., 1986; Billy-Brissac et al., 1994; Nouhou et al., 1998; North et al., 2003).

With the above considerations, the examined literature reporting FGS cases from Africa and Brazil were mapped to show their geographical distribution with the underlying prevalence of *S. haematobium* and *S. mansoni* (Fig. 1). The years of publication are classified into three groups: before 1986; between 1986 and 2000 and from 2001 to 2015. In particular, the two last groups highlight a time period before and after the World Health Assembly (WHA) resolution 54.19 in 2001, which promotes regular chemotherapy for school-age children and women to reduce morbidity. Map modified from Gryseels et al. (2006).

Fig. 1. Map indicating all publications reviewed with a considerable proportion of papers describing African cases published during the colonial era, followed by Brazil. Each hexagon represents one publication with its respective reference number. The years of publication are classified into three groups of colour shades: light colours show publications before 1986; medium colours show those between 1986 and 2000 and dark colours those from 2001 to 2015. In particular, the two last groups highlight a time period before and after the World Health Assembly (WHA) resolution 54.19 in 2001, which promotes regular chemotherapy for school-age children and women to reduce morbidity. Map modified from Gryseels et al. (2006).

4. Schistosomiasis and female genital pathologies

The clinical symptoms of FGS are in general non-specific and can be similar to those resulting from other causes. Clinical diagnosis requires trained health care professionals and/or histopathological visualisation of the eggs in the lesions. FGS cases have been reported in African women, African migrants or European or American travellers, and in some instances they had a similar clinical presentation. In the following section we highlight the pathological conditions affecting the female genital tract, however the recurrent challenge is to assess whether schistosomiasis is directly implicated in the pathological process or if it is just an incidental finding in the biopsies or in the anatomopathological tissue samples. In most of the case reports the causal relationship is well based, however in some of the cases reported in anatomopathological series the causal relationship is sometimes less obvious and the conclusions cannot be clearly supported.

4.1. Schistosomiasis and ectopic pregnancy (EP)

Ectopic pregnancy (EP) is a pregnancy that occurs outside the uterine cavity. Tubal pregnancy is the implantation of the embryo in the Fallopian tube and is the most frequent type of EP. It is potentially a deadly condition as it can occasion severe...
intra-abdominal bleeding due to tubal rupture and requires emergency surgical intervention (Bugalho et al., 1991b). EPs attributed to schistosomiasis have been repeatedly reported in many geographical areas between 1943 and 2013 and by several authors, i.e.: in Mozambique in a series of 103 cases of EPs, 4 out of 103 were attributed to a genital foci of schistosomiasis (Bugalho et al., 1991a,b). In Ivory Coast 12 out of 331 cases of EPs were associated with tubal schistosomiasis. In Loubière’s anatomo-pathological series (Loubière et al., 1977), 15 Fallopian tubes out of 32 cases of tubal schistosomiasis were removed due to tubal pregnancy. Schistosoma granuloma was always present but sometimes not prominent enough to be considered as the causal factor except in one case of a bilateral tubal schistosomiasis due to S. mansoni which was responsible for bilateral EPs (Loubière et al., 1977). Two cases of tubal pregnancies in a series of 17 uto-adenxal schistosomiasis cases were described by Drouf et al. (1973).

Although two studies from the 1970s comparing cases and controls failed to demonstrate any association between schistosomiasis and EPs (Bland and Gelfand, 1970a; Frost, 1975), tubal pregnancy was considered as the consequence of the tubal alteration due to schistosomiasis granulomata and/or salpinxitis in the anatomo-pathological analysis of a salpingectomy specimen in the following cases: Gilbert (1943), El-Bedri, (1958), Hassim, (1966), Rosen and Kim, (1974), Vass and Lucey, (1982), Yang, (1984), Okonofua et al., (1990), Ekoukou et al., (1995), Nouhou et al., (1998), Schneider and Steyn, (2000), Woto-Gaye et al., (2000), Eogan et al., (2002), Hoffmann and Baurerfeind, (2003), Garba et al., (2004), Mohammed et al., (2004), Bahrami et al., (2006), Laxman et al., (2008), Owusu-Bempah et al., (2013), Sahu et al., (2013), Aminu et al., (2014). Most of the previous cases were reported in African residents or migrants, one in a traveller, one in a Chinese resident, one in an Indian and one in an Iraqi woman. Two cases were attributed to S. mansoni and one to S. japonicum. The possible physiopathological mechanism as to how schistosomiasis can increase the risk of EP could be due to tubal submucosa alteration. Mucosal alteration have also been described (Mohammed et al., 2004), which rarely results in an obstruction but could induce a loss of tubal elasticity. This would affect the peristalsis of the tube and the ovum carriage. Fertilisation may occur and the conceptus may be implanted in the tubal mucosa instead of uterine cavity (Bland and Gelfand, 1970a). Fertilisation may occur and the conceptus may be implanted in the tubal mucosa instead of uterine cavity (Bland and Gelfand, 1970a). Fertilisation may occur and the conceptus may be implanted in the tubal mucosa instead of uterine cavity (Bland and Gelfand, 1970a). Fertilisation may occur and the conceptus may be implanted in the tubal mucosa instead of uterine cavity (Bland and Gelfand, 1970a). Fertilisation may occur and the conceptus may be implanted in the tubal mucosa instead of uterine cavity (Bland and Gelfand, 1970a).
(Madden, 1899). Many other cases of vulvo-vaginal lesions associated with schistosomiasis have been described since then. Schistosomiasis on the vulva or in the vagina, histopathologically typically consists of a granuloma or a polypoid/papillomatous tumour (Scheller, 1971; Al-Adnani and Saleh, 1982; Helling-Giese et al., 1996; Mohammed et al., 2007). Clinically it appears as a swelling, wart, sore, plaque, bleeding pseudotumoural mass (Ricosse et al., 1980; Wright et al., 1982). Vulvar schistosomiasis lesions can be easily confused with condyloma acuminata (genital warts due to Human Papilloma Virus (HPV)) (Boule and Norelov, 1964; McKee et al., 1983; Samuel and Taylor, 2015) or syphilis. Helling-Giese and colleagues have demonstrated that polyoid/papillomatous tumours, in the vagina and vulva, can be considered to be pathognomonic for FGS only in the absence of HPV infection or syphilis (Helling-Giese et al., 1996). Prominent lesions of the vulva were described in a series in Zambia in which the mean age was 18 years (S.D. = 5) (Attia et al., 1983). Descriptions of similar prominent lesions can also be found in earlier publications (Kingsley, 1969; Gras et al., 1980). In post-mortem studies (Gelfand et al., 1971; Edington et al., 1975), as in histopathological series (van Raalte et al., 1981; Al-Adnani and Saleh, 1982; Swai et al., 2006) vulvo-vaginal schistosomiasis infections are predominantly found in young girls or teenagers. Cases of vulvo-vaginal schistosomiasis have been also associated with S. mansoni (Arean, 1956). Several cases of schistosomiasis lesions of the vulva have been described in Europe and the USA in migrants (Mawad et al., 1992) or travellers (Bianchi and De Carneri, 1970; Leslie et al., 1993; Corachan et al., 1997; Blum et al., 1998; Laven et al., 1998; Carey et al., 2001; Catteau et al., 2011; Samuel and Taylor, 2015). Landry et al. (1996) described in a female traveller a case of a vulvar schistosomiasis lesion 1 year after a retrospective diagnosis of Katayama syndrome (fever due to primary schistosomiasis infection in non-immune persons). Vesico-vaginal fistulas (Servais, 1965; Ricosse et al., 1980; Kunin et al., 1996) and perianal fistulas (DeMille et al., 1995), associated with schistosomiasis, have been reported. In contrast, Bland did not find any association between schistosomiasis and vesico-vaginal fistula but patients with vesico-vaginal fistulas and schistosomiasis were less likely to heal after surgical procedures than those who did not have schistosomiasis (Bland and Gelfand, 1970b).

4.5. Schistosomiasis and uterine body-associated pathology

As previously noted clinical cases of schistosomiasis with uterine body involvement are underreported compared with the frequently described uterine body involvement in post-mortem studies. This contradiction was already noted by Attia in his review (Attia, 1962). In some recent publications, S. mansoni and S. haematobium infections have been associated with leiomyoma of the uterus, a pathology which is known to frequently affect sub-Saharan African women (Boers et al., 2003; Mayr et al., 2005; Cavalcanti et al., 2011; Hillers and Wiersma, 1961). A case of endometritis due to the presence of the parasite in the intramural uterine vein in a 42 year old Chinese woman (Ching-ch'ien, 1951) and a Japanese case with endometrial schistosomiasis were reported (Sugiyama et al., 1963). Cases of schistosomiasis associated with pregnancy have been associated with stillbirths (Narabayashi, 1914 cited in Carpenter et al., 1964; Youssef and Abidine, 1958; Sutherland et al., 1965; Berry, 1966; Bittencourt et al., 1986). One case control study examined the impact of schistosomiasis on birth weight. While not showing any differences in the delivery term, it did show that schistosomiasis in pregnant women was significantly associated with low birth weight in preterm deliveries (Siegrist and Siegrist-Oblimpeh, 1992).

4.6. Schistosomiasis and cervical alterations

In anatomopathological case series and post-mortem studies, the uterine cervix is the female genital organ most frequently affected by schistosomiasis. Cervical schistosomiasis has been the most studied aspect of FGS with many studies conducted during the last 20 years by Feldmeier, Kjetland and associates. FGS clinical presentation can be similar to other gynaecological pathologies (sexually transmitted infection, endometriosis, etc). Several clinical signs and symptoms have been significantly associated with cervical schistosomiasis such as low abdominal pain, irregular menstruation, cervical contact bleeding, abnormal vaginal discharge, dysparuria, vaginal or cervical polyps, contact bleeding, vulval itching and chronic cervicitis (Leutsch et al., 1998; Anosike et al., 2003; Talaat et al., 2004; Swai et al., 2006). Rubbery papules, sandy patches and neovascularization are cervical lesions that have been statistically strongly associated with S. haematobium, (Kjetland et al., 2005; Randrianasolo et al., 2013) and with S. mansoni (Poggensee et al., 2001); grainy and yellow sandy patches and rubbery papules being considered pathognomonic of cervical schistosomiasis (Kjetland et al., 2012, 2014; Norseth et al., 2014). In Europe and in the USA several cases of schistosomiasis have been diagnosed through cervical smears of women with dysplasia (Adeniran et al., 2003; Chenault and Hoang, 2006; Dzeing-Ella et al., 2009; Chen et al., 2012). Endocervical forms of schistosomiasis such as polyps have been described as well (Eladl et al., 2012; Delmondes et al., 2014). Three cases of schistosomiasis have been reported in HIV patients with cervical dysplasia or carcinoma with HPV (Chenault and Hoang, 2006; Rachaneni et al., 2007; Toller et al., 2015). In an observational study conducted in the Limpopo province in South Africa, van Bogaert (2011) found an HIV prevalence of 14% in 234 women with biopsy-confirmed FGS, which is the expected HIV prevalence in this region; schistosomiasis cervical involvement was observed in the large majority of HIV-positive women and more frequently than in the whole study group of (HIV+ and HIV−) women with FGS (94% versus 54%). Intraepithelial neoplasia was observed more frequently in HIV-positive women than in the whole studied group (50% versus 17.5%). HIV-infected women were significantly older than women with FGS who were not infected with HIV (42 versus 35 years; P = 0.003) (van Bogaert, 2011).

5. Schistosoma haematobium and HIV

In 1995, the first article suggesting FGS as a risk factor for HIV was published, establishing a plausibility and prevalence correlation between HIV and urinary schistosomiasis (Feldmeier et al., 1995a,b). Since then, several studies documented that schistosomiasis of the uterine cervix is associated with disrupted epithelia, neovascularisation, contact bleeding or spontaneous bleeding (Wright et al., 1982; Poggensee et al., 2000; Kjetland et al., 2005, 2006a,b, 2009; Swai et al., 2006; Jourdan et al., 2011b, 2013), and a higher density of HIV target cells; factors that predispose to HIV infection (Jourdan et al., 2011a; Kleppa et al., 2014). While the association between S. haematobium and HIV has been documented in several observational studies, the association between S. mansoni and HIV is less clear. Two case control studies performed in comparable groups and adjusted for the main confounding factors showed two- to four-fold increased odds of HIV in women with FGS due to S. haematobium (Kjetland et al., 2006b) or urogenital schistosomiasis (Downs et al., 2011). In an ecological study including 43 sub-Saharan African countries Ndëffo Mbah et al. (2013b) demonstrated that each infection with S. haematobium per 100 individuals was associated with a 2.9% relative increase in HIV infection (95% CI: 0.2–5.8%; P = 0.038).
Three mathematical modelling studies have shown a correlation between HIV and schistosomiasis epidemics and an impact of schistosomiasis treatment on the HIV epidemic (Gibson et al., 2010; Mushayabasa and Bhunu, 2011; Ndeffo Mbah et al., 2013a). Furthermore, one of these studies showed the cost effectiveness of a schistosomiasis intervention on HIV infection prevention (Ndeffo Mbah et al., 2014). The main limitation of the above cited observational studies is that they cannot prove causality and some relevant confounding factors may have been missed.

The interpretation of the results could be wrong if HIV infection would occur before FGS and if it would induce more severe FGS lesions (as it is the case for cervical dysplasia). Schistosomiasis age prevalence curves and its genital manifestation before the onset of sexual activity tend to make more it probable that schistosomiasis infection and its related genital lesions occur before HIV infection (Poggensee et al., 2000; Kjetland et al., 2005; Hegertun et al., 2013). Moreover FGS clinical presentation does not differ in HIV-infected women versus HIV non-infected women (Kleppa et al., 2015). Egg excretion in urine might be increased in HIV-positive women which would overestimate the association but several studies have shown that egg excretion tends to be similar or even lower in HIV-infected individuals with urinary schistosomiasis (N’Zoukoudi-N’doundou et al., 1995; Mwanakasale et al., 2003; Kallestrup et al., 2005; Kleppa et al., 2015).

6. Cervical schistosomiasis, HPV and cervical carcinoma

It is well established that cervical carcinoma is mainly due to HPV infection. While the association between schistosomiasis and cervical carcinoma remains unclear, several cases of cervical carcinoma associated with schistosomiasis have been reported many years ago (Chaves, 1966; Pimentafilho, 1964). In two histopathological series, cervical carcinoma was found in 9–10% of the studied cervical schistosomiasis cases (Badawy, 1962; Gwavava et al., 1984). Payet and Camain (cited in Gwavava et al. (1984)) found four cases of cervical cancer associated with schistosomiasis in a series of 38 cervical carcinoma cases. Youssef reported 15 cases of invasive cervical carcinoma in which Schistosoma eggs were visualised microscopically out of 121 cases of cervical schistosomiasis (Youssef et al., 1970). On the other hand, other studies found no association between cervical carcinoma and schistosomiasis (Williams, 1967; Coelho et al., 1979; Wright et al., 1982; Szela et al., 1993). However, in one study when no association between cervical cancer and cervical schistosomiasis was found, it was observed that women affected with both schistosomiasis and cervical cancer were significantly younger than those affected by cervical cancer only (Moubayed et al., 1994, 1995). This could reflect the fact that young girls are more at risk of having FGS but it could also be compatible with the hypothesis that schistosomiasis could increase the carcinogenic effect of HPV infection on the uterine cervix by predisposing to HPV infection or favouring its persistence as several authors have hypothesised. Indeed Petry and colleagues (2003) found a higher proportion of high risk HPV in the genitals of women from a schistosomiasis endemic area compared with controls (Poggensee et al., 1999; Poggensee and Feldmeier, 2001; Petry et al., 2003). More recently a longitudinal study showed that the development of high-grade squamous intraepithelial neoplasia was significantly associated with FGS of a minimum of 5 years duration, while no association was found between FGS and persistent high-risk HPV (Kjetland, 2010).

7. Discussion

The majority of the publications examined in this review were case reports or case series. The few general population based studies were mostly performed in S. haematobium endemic areas. Despite the relatively similar methodology, these studies revealed significantly different results, which most likely reflected the prevalence and intensity of schistosomiasis in the studied areas. However, other reasons cannot be excluded and deserve further research. Equally relevant is the lack of population studies in areas endemic to S. mansoni (and eventually S. japonicum), given the abundance of case reports of FGS associated with this species, particularly in Brazil (Fig. 1). Traditionally, the interface between parasitology and gynaecology has been weak and largely focused on diseases caused by protists e.g. Trichomonas vaginalis. It has been only recently appreciated that helminths, and particularly schistosomiasis, cause significant damage to the female genitalia, as highlighted in a relevant WHO document (WHO, 2016a).

Today, we appreciate many of the possible consequences of FGS such as EP, infertility, spontaneous abortion, low premature infant birth weight, possibly cervical cancers, cervical lesions and especially its probable role in increasing susceptibility to other infections such as HIV/AIDS, however we lack reliable up-to-date epidemiological information on prevalence, incidence and geographical distribution of FGS. We can only make conservative estimates of the overall prevalence of the disease and of the 250 million people infected with schistosomiasis, approximately two-thirds of whom (ca. 170 million) are infected by the urogenital form caused by S. haematobium (the form with the highest correlation with cases of FGS). Among those 170 million, half of them are women (ca. 85 million) and at least one-third of those women may suffer from FGS. Of them, probably 20 million are girls or young women, most of them lacking suitable medical attention (Hotez and Whitham, 2014). We consider that this lack of validated epidemiological information is the major impediment towards bringing FGS to the forefront of strategic discussions not only in the context of schistosomiasis disease control interventions, but perhaps even more importantly, in the context of addressing women’s health in the broadest sense including mental health, sexually transmissible diseases, cancer and reproductive/maternal health. This is especially important when considered in the context of achieving the 2030 Sustainable Development Goals (SDGs) and particularly SDG 3: “Ensure healthy lives and promote well-being for all at all ages”. FGS falls within the targets set for SDG3 on at least two accounts: “By 2030, ensure universal access to sexual and reproductive health-care services, including for family planning, information and education, and the integration of reproductive health into national strategies and programmes” and “By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases”. (SDG 3 www.un.org/sustainabledevelopment/sustainable-development-goals).

When examining the case reports, the vast majority of those were in the context of medical care reports from women living in schistosomiasis endemic countries or from individual cases of tourists who acquired FGS in sub-Saharan countries and were diagnosed in the well-equipped health care facilities of western countries. In those reports it was often difficult to be affirmative regarding the causal relationship between schistosomiasis and the described pathology. The high number of FGS descriptions to date has had little impact on performing large scale population based studies to estimate more precisely the FGS burden and to address its public health implications, particularly in relation to gynaecological health or to highly prevalent infections such as HIV or HPV. Therefore, well designed prospective studies addressing the full spectrum of potential target organs, particularly the upper genital tract (Richert et al., 1995), should be conducted in various schistosomiasis endemic areas (including S. mansoni and S. japonicum).
The main challenge when planning or conducting the above suggested studies resides in the difficulty associated with the diagnosis of FGS. While for FGS affecting the uterine cervix and vagina the recently published WHO pocket atlas (http://pocketatlas.org) and the supporting material sets clear criteria to identify the lesions (Norseth et al., 2014), much work is needed to address the diagnosis of lesions in other organs (Richter et al., 1995). Furthermore, even with the available tools there is a great need for trained personnel and appropriate equipment which are not available in many endemic areas.

In terms of disease management, the current gold standard to treat schistosomiasis is a single dose of 40 mg/kg of praziquantel according to the WHO recommendation (WHO, 2016, http://www.who.int/schistosomiasis/strategy/en/). Treatment with praziquantel kills the adult worms and provides some regression of inflammatory lesions. However, the recommended regimen is probably not sufficient to prevent and eliminate the eggs associated with FGS (Richter et al., 1996; Poggensee and Feldmeier, 2001; Kjetland et al., 2006a, 2008; Downs et al., 2013). As a preventive measure, regular praziquantel treatment starting in early childhood (including pre-school age children) could be the most effective intervention to prevent the occurrence and development of future complications associated with genital schistosomiasis. However, for a patient who presents herself with severe symptoms of FGS there are no validated therapeutic options. Therefore, there is a great need to search for treatment alternatives, focussing on reducing the pathological process induced by the Schistosoma eggs, alternative praziquantel doses or regimens aiming to achieve total reducing the pathological process induced by the egg production that sustains the pathology.

8. Conclusion

The clinical manifestations of FGS, since first reported in the Lancet in 1899 (Madden, 1899), have been continuously described through time in most schistosomiasis endemic areas affected by different Schistosoma spp. While the original descriptions mostly highlighted the macroscopic external lesions of the female genital tract, today we know that it can affect all of the genital tract with serious health implications. On the other hand, given the nature of the reports, it is difficult to establish how large or extensive the current burden of disease is; thus only crude extrapolations are possible. FGS appears to be a prevailing condition even with the progress achieved in the implementation of schistosomiasis control strategies. Strategies fundamentally focus on (morbidity) prevention while proper clinical and laboratory diagnosis of FGS remains a significant issue and bottleneck. Women suffering from FGS approach health care providers with complaints about bleeding, infertility or suspicion of having sexually transmitted infections, however little attention is provided because the nature of the disease. On the other hand, given the nature of the reports, it is difficult to establish how large or extensive the current burden of disease is; thus only crude extrapolations are possible. FGS appears to be a prevailing condition even with the progress achieved in the implementation of schistosomiasis control strategies. Strategies fundamentally focus on (morbidity) prevention while proper clinical and laboratory diagnosis of FGS remains a significant issue and bottleneck. Women suffering from FGS approach health care providers with complaints about bleeding, infertility or suspicion of having sexually transmitted infections, however little attention is provided because the nature of the disease.